ADC
Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data
June 21, 2024 17:30 ET | Novotech
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of...
22157.jpg
Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics
June 20, 2024 04:23 ET | Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. In recent...
Alira Health Partner
Alira Health Partners with Scottsdale Research Institute for Psilocybin Clinical Trials Funded by the State of Arizona
June 18, 2024 09:00 ET | Alira Health
Framingham, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Alira Health, a global advisory and clinical research firm, announced today its collaboration with the Scottsdale Research Institute (SRI) to...
Science 37 Logo.jpg
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024 15:55 ET | Science 37, Inc.
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
Verana+logo+horizontal.jpg
Verana Health Committed to Revolutionizing Clinical Trials with Enhancements to SaaS Applications
June 12, 2024 09:00 ET | Verana Health, Inc.
SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), announces new...
Science 37 Logo.jpg
Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024 08:00 ET | Science 37, Inc.
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study.
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
June 12, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...
22157.jpg
Global mRNA Cancer Vaccines Clinical Trials Market Report 2024: First Commercial mRNA Vaccine Approval Expected by 2029
June 12, 2024 07:32 ET | Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024" drug pipelines has been added to ResearchAndMarkets.com's...
Logo.png
CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials
June 11, 2024 09:00 ET | CanaQuest Medical Corp.
Appointee, formerly with GW Pharma (subsidiary), brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex®) TORONTO, ON, June 11, 2024 ...
Allyx.jpg
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
June 11, 2024 08:00 ET | Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.